中文名稱:pLVX-AcGFP1-C1 載體 | 英文名稱:pLVX-AcGFP1-C1 |
保存條件: 常溫運(yùn)輸 | 純度規(guī)格: 99% |
產(chǎn)品類別: 質(zhì)粒/載體 |
pLVX-AcGFP1-C1 is an HIV-1-based, lentiviral expression vector that allows you to express your gene of interest fused to AcGFP1, a green fl uorescent protein derived from Aequorea coerulescens. Genes cloned into the multiple cloning site (MCS), located at the C-terminal end of the AcGFP1 coding sequence, are expressed as C-terminal fusions of the AcGFP1 protein. Expression of the fusion protein is driven by the constitutively active human cytomegalovirus immediate early promoter (PCMV IE) located just upstream of the AcGFP1 coding sequence. Lentiviral particles derived from the vector allow the expression of AcGFP1 fusion proteins in virtually any cell type, including primary cells. The unmodified vector expresses AcGFP1, and may be used to produce marker virus to optimize infection protocols. pLVX-AcGFP1-C1 contains all of the viral processing elements necessary for the production of replication-incompetent lentivirus, as well as elements to improve viral titer, transgene expression, and overall vector function. The woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) promotes RNA processing events and enhances nuclear export of viral and transgene RNA (1), leading to increased viral titers from packaging cells, and enhanced expression of your gene of interest in target cells. In addition, the vector includes a Rev-response element (RRE), which further increases viral titers by enhancing the transport of unspliced viral RNA out of the nucleus (2). Finally, pLVX-AcGFP1-C1 also contains a central polypurine tract (cPPT) element that increases nuclear importation of the viral genome during target cell infection, resulting in improved vector integration and more efficient transduction (3). In addition to lentiviral elements, pLVX-AcGFP1-C1 contains a puromycin resistance gene (Puromycin resistance) under the control of the murine phosphoglycerate kinase (PGK) promoter (PPGK) for the selection of stable transductants. The vector also contains a pUC origin of replication and an E. coli ampicillin resistance gene (Ampr) for propagation and selection in bacteria.
pLVX-AcGFP1-C1 constitutively expresses your gene of interest from PCMV IE when transduced into target cells. Before the vector can be transduced into cells, however, it must be transfected into 293T packaging cells with our Lenti-X™ HT Packaging System (Cat. Nos. 632160 and 632161). This packaging system allows you to safely produce high titer, infectious, replication-incompetent, VSV-G pseudotyped lentiviral particles that can infect a wide range of cell types, including non-dividing and primary cells (4).
特別提示:本公司的所有產(chǎn)品僅可用于科研實(shí)驗(yàn),嚴(yán)禁用于臨床醫(yī)療及其他非科研用途!
成立日期 | 2016-08-08 (9年) | 注冊資本 | 100萬元整 |
員工人數(shù) | 1-10人 | 年?duì)I業(yè)額 | ¥ 100萬以內(nèi) |
主營行業(yè) | 生物化工,有機(jī)原料,化學(xué)試劑,醫(yī)藥原料,技術(shù)服務(wù) | 經(jīng)營模式 | 貿(mào)易,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP6年
|
上海弘順生物科技有限公司
|
2024-11-16 | |
¥1666 |
VIP6年
|
成都彼樣生物科技有限公司
|
2024-11-15 | |
詢價(jià) |
明光市興欣礦業(yè)有限責(zé)任公司
|
2024-11-15 |